http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021254868-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1384122f4f2f761c455ec3b7b4ce00da http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_307b6dad57756d6b38a4c593d68d6655 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
| filingDate | 2021-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fedc6236112b0fba050236bded44a3b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a9dac3581155ea1687738db8ec69a79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9524a6e8ecf364a67e68291368b05dc1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71d0c08ea9022aaac4a52d699a50dbea |
| publicationDate | 2021-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021254868-A1 |
| titleOfInvention | Multiplex sars-cov-2 immunoassay |
| abstract | The present invention provides methods and tools to determine a serological signature of antibodies against SARS-CoV-2 from a biological sample of a subject. More particularly, a method is provided for the detection of antibodies against SARS-CoV-2 in a biological sample from a subject comprising contacting the sample with a combination of antigens comprising at least one membrane antigen derived from SARS-CoV-2, at least one nucleocapsid antigen derived from SARS-CoV-2, at least one spike antigen derived from SARS-CoV-2, and optionally a T. cruzi antigen, wherein said antigens are immobilized on a solid support spatially separated from one another, and detecting the formed antigen/antibody complexes to determine a serological signature. The invention further provides a solid support and a kit for detecting antibodies against SARS-CoV-2 in a sample according to the invention. The invention further provides a method for the diagnosis and/or prognosis of a SARS-CoV-2 infection in a subject, a method for classifying a subject into a group informative of the clinical severity of a SARS- CoV-2 infection, a method for monitoring the (clinical) progression of a SARS-CoV-2 infection in a subject, a method for predicting the effectiveness of a vaccination in a subject, a method for identifying a subject who has neutralizing antibodies to SARS-CoV-2 and a method for determining a SARS-CoV-2 neutralizing antibody titer, said methods encompassing the determination of a serological signature according to a method of the invention and comparison with an appropriate reference serological signature. |
| priorityDate | 2020-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.